Stockreport

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

XORTX Therapeutics Inc.  (XRTX) 
PDF • VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 202 [Read more]